AXSM Q3 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+243.1% YoY

Gross Profit

$51M88.7% margin

Operating Income

-$62M-107.5% margin

Net Income

-$62M-107.6% margin

EPS (Diluted)

$-1.32

QoQ Revenue Growth

+23.8%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$601M

Total Liabilities

$331M

Stockholders' Equity

$270M

Cash & Equivalents

$417M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$17M	+243.1%
Gross Profit	$51M	$15M	+243.5%
Operating Income	-$62M	-$42M	-46.5%
Net Income	-$62M	-$45M	-38.8%

Revenue Segments

License

$66M53%

Product

$57M46%

Royalty

$667,0001%

Geographic Segments

UNITED STATES

$56M98%

Non-US

$1M2%